Piper Sandler lifts Claritev stock rating to Overweight, PT to $44

Published 29/05/2025, 06:56
Piper Sandler lifts Claritev stock rating to Overweight, PT to $44

On Thursday, Claritev shares (NYSE:CTEV) received a significant boost from Piper Sandler, with the investment firm upgrading the stock’s rating from Neutral to Overweight and more than doubling the price target to $44 from $19. Currently trading at $26.66, the stock has shown remarkable momentum with a 238% surge over the past six months, according to InvestingPro data. The upgrade was spurred by Claritev’s impressive first quarter financial performance, which included revenue and adjusted EBITDA surpassing expectations, despite the company’s LTM revenue of $927.45 million showing a slight decline.

Piper Sandler’s optimism is rooted in several key developments for Claritev, including a three-year contract renewal with ELV and the establishment of strategic commercialization partnerships. These factors, along with robust bookings and a growing project pipeline, are believed to effectively address concerns regarding customer concentration risk. However, InvestingPro analysis reveals some challenges, including significant cash burn and a substantial debt burden with a debt-to-equity ratio of 313%. These strategic moves have nonetheless reinforced Piper Sandler’s confidence in Claritev’s ability to meet its reiterated calendar year 2025 guidance and to continue growth into 2026.

The reassessment of Claritev’s outlook prompted Piper Sandler to increase the target multiple to 9.0 times the projected adjusted EBITDA for calendar year 2026, up from the previous multiple of 8.0. This adjustment reflects a more favorable view of Claritev’s fundamental prospects. However, the firm also acknowledges that risks remain, including those related to customer concentration, execution, and various legal and regulatory challenges, as well as balance sheet considerations. These factors are taken into account when comparing Claritev to peers such as Premier Inc. (PINC) and Change Healthcare (NASDAQ:CHNG).

Piper Sandler’s analysis, detailed on page 2 of their report, underpins the revised price target, which represents a substantial increase from the prior target. This new price target of $44 marks a significant change in the firm’s valuation of Claritev’s stock and signals a potentially stronger performance ahead for the company.

In other recent news, Claritev Corporation reported a decline in its Q1 2025 revenue to $231.3 million, representing a 1.4% decrease from the previous year. Despite this downturn, the company has reaffirmed its full-year revenue guidance and remains optimistic about returning to growth in the upcoming quarters. Claritev’s Payment and Revenue Integrity segment showed notable growth, increasing by 9.7% year-over-year. Additionally, Claritev has entered into a strategic partnership with Burjeel Holdings to enhance revenue cycle management in the Middle East and North Africa region, with expectations of generating revenue by 2025.

The partnership aims to leverage Claritev’s technology and Burjeel’s regional expertise to develop new solutions. In analyst updates, no specific upgrades or downgrades were mentioned for Claritev, but the company is focusing on international expansion and new revenue models. Claritev also highlighted its new partnership with Lantern, which is expected to enhance its product offerings. These developments reflect Claritev’s ongoing efforts to address market challenges and expand its global presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.